Diferencia entre revisiones de «Template:Antibiotics Ludwigs Immunocompromised»
Sin resumen de edición |
(Marked this version for translation) |
||
| Línea 2: | Línea 2: | ||
<translate> | <translate> | ||
====Immunocompromised<ref>Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503</ref>==== | ====Immunocompromised<ref>Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503</ref>==== <!--T:1--> | ||
<!--T:2--> | |||
*[[Special:MyLanguage/Cefepime|Cefepime]] 2 g IV q12 hrs + [[Special:MyLanguage/Metronidazole|Metronidazole]] 500 mg IV q6 hrs OR | *[[Special:MyLanguage/Cefepime|Cefepime]] 2 g IV q12 hrs + [[Special:MyLanguage/Metronidazole|Metronidazole]] 500 mg IV q6 hrs OR | ||
*[[Special:MyLanguage/Meropenem|Meropenem]] 1 g IV q8 hrs OR | *[[Special:MyLanguage/Meropenem|Meropenem]] 1 g IV q8 hrs OR | ||
Revisión del 08:25 23 ene 2026
Immunocompromised[1]
- Cefepime 2 g IV q12 hrs + Metronidazole 500 mg IV q6 hrs OR
- Meropenem 1 g IV q8 hrs OR
- Imipenem/Cilastatin 500mg (20mg/kg) IV q6 hours
- Piperacillin-tazobactam 4.5g (80mg/kg) IV q6 hours
- Add Vancomycin 15-20 mg/kg IV q8 hrs (max 2 g per dose) if concern for MRSA risk factors
- ↑ Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503